Physician profile
Karen Springfield
NPI 1760766430
$4,796.72
in general payments reported to CMS, 2019-2025
38 companies · $988 in 2025
The $988 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $935 · 2022: $784 · 2023: $1,151 · 2024: $939 · 2025: $988.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,077.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,025.85 | 2021-2025 | |
| Novo Nordisk INC | $709.63 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $469.64 | 2021-2025 | Farxiga, Breztri |
| Pfizer INC. | $417.23 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $365.74 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $163.10 | 2021-2024 | Xarelto |
| Amgen INC. | $147.96 | 2021-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $142.14 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Novartis Pharmaceuticals Corporation | $137.10 | 2022-2025 | |
| Astellas Pharma US INC | $127.08 | 2021-2025 | Veozah |
| Glaxosmithkline, LLC. | $103.44 | 2022-2025 | Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $75.11 | 2021-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $73.56 | 2021 | |
| Sumitomo Pharma America, INC. | $71.29 | 2023-2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $68.68 | 2023 | Quviviq |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Springfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.